Synthesis and characterization of Rosuvastatin calcium impurity A; a HMG-CoA reductase inhibitor
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Young Hee | - |
dc.contributor.author | Viji, Mayavan | - |
dc.contributor.author | Lee, Eunhwa | - |
dc.contributor.author | Jo, Hyeju | - |
dc.contributor.author | Yoo, Kyung | - |
dc.contributor.author | Sim, Jaeuk | - |
dc.contributor.author | Lee, Sunhwan | - |
dc.contributor.author | Lee, Kiho | - |
dc.contributor.author | Lee, Heesoon | - |
dc.contributor.author | Jung, Jae-Kyung | - |
dc.date.accessioned | 2021-09-03T04:48:05Z | - |
dc.date.available | 2021-09-03T04:48:05Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-06-28 | - |
dc.identifier.issn | 0040-4039 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/83082 | - |
dc.description.abstract | During the process development for multistep synthesis of Rosuvastatin calcium several impurities were obtained along with the final Rosuvastatin calcium. Out of this; synthesis of impurity A (acetone adduct) a minor impurity of Rosuvastatin calcium (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-[[(2-hydroxy-2-methyl-propyl)sulfonyl(methyl)amino]-6-(1-methylethyl)-pyrimidin-5-y1]-3,5-dihydroxyheptenoicacid hemicalcium salt, is described. The synthesis of impurity A has been accomplished in 6 steps; starting from formation of beta-hydroxy sulfonamide as the key intermediate and followed by using convenient routes with overall yield of 13.5%. The target compound can be used as the reference substance of impurity of the Rosuvastatin calcium. (C) 2017 Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.subject | BIOLOGICAL-ACTIVITY | - |
dc.subject | HYPERCHOLESTEROLEMIA | - |
dc.subject | STATINS | - |
dc.subject | HYPERTRIGLYCERIDEMIA | - |
dc.subject | EFFICACY | - |
dc.subject | THERAPY | - |
dc.subject | SAFETY | - |
dc.title | Synthesis and characterization of Rosuvastatin calcium impurity A; a HMG-CoA reductase inhibitor | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Kiho | - |
dc.identifier.doi | 10.1016/j.tetlet.2017.05.075 | - |
dc.identifier.scopusid | 2-s2.0-85019755110 | - |
dc.identifier.wosid | 000404200700021 | - |
dc.identifier.bibliographicCitation | TETRAHEDRON LETTERS, v.58, no.26, pp.2614 - 2617 | - |
dc.relation.isPartOf | TETRAHEDRON LETTERS | - |
dc.citation.title | TETRAHEDRON LETTERS | - |
dc.citation.volume | 58 | - |
dc.citation.number | 26 | - |
dc.citation.startPage | 2614 | - |
dc.citation.endPage | 2617 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Organic | - |
dc.subject.keywordPlus | BIOLOGICAL-ACTIVITY | - |
dc.subject.keywordPlus | HYPERCHOLESTEROLEMIA | - |
dc.subject.keywordPlus | STATINS | - |
dc.subject.keywordPlus | HYPERTRIGLYCERIDEMIA | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordAuthor | Statins | - |
dc.subject.keywordAuthor | Rosuvastatin calcium | - |
dc.subject.keywordAuthor | HMG-CoA reductase inhibitor | - |
dc.subject.keywordAuthor | Drug impurities | - |
dc.subject.keywordAuthor | beta-Hydroxy sulfonamide | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.